Vertex Pharmaceuticals Incorpor (VRTX) Stock Price & How to Invest

Last updated November 2026

Short answer

You can invest in Vertex Pharmaceuticals (VRTX) by buying shares or fractional shares at any major broker, through a healthcare or biotech ETF that holds it, or as one holding in a thematic basket. Vertex is the dominant, effectively sole maker of medicines that treat the underlying cause of cystic fibrosis, a franchise led by Trikafta/Kaftrio and its next-generation successor Alyftrek that generated the bulk of the company's roughly $12.0 billion in 2025 revenue at very high margins. The company is now trying to prove it can grow beyond that near-monopoly, with a non-opioid acute-pain drug (Journavx), an endocrinology franchise bought with its roughly $10 billion cash acquisition of Crinetics Pharmaceuticals (closed in September 2026), a gene therapy for sickle cell disease and beta thalassemia (Casgevy, partnered with CRISPR Therapeutics), and pipeline programs in type 1 diabetes and kidney disease. The single biggest risk is concentration: cystic fibrosis still drives the overwhelming majority of revenue, so the newer launches and pipeline must succeed for the growth story to broaden beyond one disease.

VRTX stock price

As of 2026-11-16, Vertex Pharmaceuticals Incorpor (VRTX) last closed at $537.79, up 23.9% over the past year. Over the past 52 weeks it has traded between $421.03 and $558.88.

VRTX last close
$537.79
1 day
-0.15%
1 month
+7.61%
1 year
+23.91%
52-week range
$421.03 to $558.88
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Vertex Pharmaceuticals Incorpor's investor relations page. Walnut is informational, not investment advice.

VRTX key stats

At $537.79 on November 16, 2026, Vertex Pharmaceuticals Incorpor (VRTX) has a market cap of $136B and a P/E of 34.6 on trailing earnings (27.0 on forward earnings).

Market cap
$136B
P/E (trailing)
34.6
P/E (forward)
27.0
EPS (trailing 12 months)
$15.54
Price to book
6.5
Beta
0.28

Market cap, P/E and yield are measured at the $537.79 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Vertex Pharmaceuticals Incorpor (VRTX)?

The last two weeks for Vertex Pharmaceuticals Incorpor, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • VRTX closed at $537.79 on November 16, 2026, down 2.4% over the past five trading days (from $550.87).
  • On November 3, 2026, Vertex Pharmaceuticals Incorpor filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 4, 2026, Barclays raised its target to $626.00 from $617.00 (Overweight).
  • On November 3, 2026, JP Morgan raised its target to $570.00 from $560.00 (Overweight).
  • On November 3, 2026, Goldman Sachs raised its target to $725.00 from $654.00 (Buy).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Vertex Pharmaceuticals Incorpor (VRTX) latest quarter

Vertex Pharmaceuticals reported revenue of $3.4 billion for Q3 2026, up 12% from a year earlier (Vertex Pharmaceuticals, Nov 2, 2026).

Revenue
$3.4 billion
up 12% from a year earlier
Diluted EPS (GAAP)
$2.56
down 39% from a year earlier
Total CF product revenues
$3.3 billion
up 8% from a year earlier

Source: Vertex Q3 2026 results, Nov 2, 2026. Full earnings breakdown

What does Vertex Pharmaceuticals Incorpor (VRTX) do?

Vertex Pharmaceuticals is a Boston-based biotechnology company that designs medicines targeting the root molecular cause of serious diseases rather than only their symptoms. Its foundation is cystic fibrosis (CF), a genetic disease in which a defective CFTR protein disrupts salt and water movement in cells, damaging the lungs and other organs. Vertex developed the first drugs that correct the underlying protein defect, progressing from Kalydeco to Orkambi and Symdeko and then to the breakthrough triple-combination Trikafta (marketed as Kaftrio in Europe), which treats the large majority of CF patients. In late 2024 it began rolling out Alyftrek, a next-generation once-daily successor designed to extend that franchise and its patent protection. Because CF is a rare disease with essentially no competing root-cause therapy, Vertex has enjoyed pricing power and durable, high-margin revenue.

Vertex has spent years reinvesting that cash to diversify beyond CF, and several of those bets are now on the market. Casgevy, developed with CRISPR Therapeutics, is a CRISPR gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia and was among the first approved CRISPR medicines. Journavx (suzetrigine) is a non-opioid painkiller that blocks the NaV1.8 sodium channel, approved for moderate-to-severe acute pain and positioned as an alternative to opioids. In the pipeline, zimislecel is a stem-cell-derived islet therapy aiming to functionally cure type 1 diabetes, suzetrigine is in Phase 3 for diabetic peripheral neuropathic pain, and inaxaplin targets APOL1-mediated kidney disease. For full-year 2025 Vertex reported total revenue of roughly $12.0 billion, up about 9 percent, and it guided 2026 revenue to roughly $12.95 billion to $13.1 billion.

The biggest change since mid-2026 is a move into hormone disorders. In September 2026 Vertex closed its acquisition of Crinetics Pharmaceuticals for about $10 billion in cash, the largest deal in its history. Crinetics brings Palsonify, a once-daily oral pill approved in the US for acromegaly (excess growth hormone), and atumelnant, in Phase 3 for congenital adrenal hyperplasia and Phase 2 for Cushing's syndrome; Vertex estimates combined peak sales above $5 billion. Operationally, Q2 2026 revenue was ~$3.33 billion, up ~12.5% year over year, with EPS of $4.73 essentially matching the $4.75 consensus. Trailing twelve-month revenue reached ~$12.6 billion and net income ~$4.4 billion. As of October 16, 2026, VRTX closed near $504.24, up ~12% year to date and ~23% over one year. Q3 results are due November 2, 2026; consensus EPS of only ~$0.04, against ~$4.50 to $4.75 in recent quarters, suggests analysts expect large one-time costs tied to the Crinetics deal.

What's driving Vertex Pharmaceuticals Incorpor (VRTX)?

1. A durable, high-margin cystic fibrosis near-monopoly

Vertex remains effectively the only company selling root-cause CF therapies, and demand for Trikafta/Kaftrio continues to grow through label expansions into younger age groups and additional geographies. The launch of Alyftrek, a once-daily successor, both improves convenience and extends intellectual-property protection on the franchise into the 2030s and beyond. This base business throws off the cash that funds the entire diversification effort, and management continues to pursue approvals for children as young as one to two years old.

2. Journavx opens a large non-opioid pain market

Journavx (suzetrigine) is a first-in-class non-opioid NaV1.8 pain inhibitor approved for moderate-to-severe acute pain, addressing a market where prescribers and payers want alternatives to addictive opioids. Vertex is also running two Phase 3 trials of suzetrigine in diabetic peripheral neuropathic pain, a large chronic-pain indication that would substantially expand the drug's reach if successful. Together with Casgevy, non-CF products delivered more than a quarter of Vertex's revenue growth in the first quarter of 2026.

3. Cell and genetic therapies aimed at functional cures

Casgevy, partnered with CRISPR Therapeutics, is one of the first approved CRISPR gene-editing medicines and treats sickle cell disease and transfusion-dependent beta thalassemia, though its complex manufacturing means a gradual ramp. In the pipeline, zimislecel is an islet-cell therapy for type 1 diabetes that has shown patients achieving insulin independence in early data, with global regulatory submissions expected in 2026. These programs target diseases where a one-time therapy could be transformative and command premium pricing.

4. A cash-rich balance sheet funding pipeline and deals

Vertex operates with a large net cash position and strong operating cash flow, which lets it fund an unusually broad pipeline internally and pursue acquisitions and licensing without straining its finances. It has expanded into kidney disease with inaxaplin for APOL1-mediated kidney disease and, in September 2026, into endocrinology with the roughly $10 billion cash purchase of Crinetics and its acromegaly drug Palsonify. Before that deal Vertex held ~$7.85 billion of cash against ~$2 billion of debt at the end of June 2026, so the purchase uses a large share of the war chest. This financial firepower is what gives the diversification strategy multiple independent chances to work rather than betting everything on one asset.

What are the risks to Vertex Pharmaceuticals Incorpor (VRTX)?

The central risk is revenue concentration: cystic fibrosis still accounts for the overwhelming majority of Vertex's sales, so any disruption, whether a safety signal, a competing modulator, or pricing pressure, would hit the core disproportionately, and the newer products remain small by comparison. Clinical and regulatory risk is elevated because the growth thesis depends on pipeline programs (zimislecel in type 1 diabetes, suzetrigine in chronic pain, inaxaplin in kidney disease) that could fail in trials or face approval delays, as happened with an earlier pain candidate. Casgevy's ramp is slow because gene therapy requires specialized centers and lengthy patient preparation, so near-term contribution is modest. The stock also trades at a premium valuation that prices in successful diversification, meaning disappointments can trigger sharp derating, and drug-pricing policy and eventual CF patent expirations are long-term overhangs. The Crinetics acquisition adds integration and launch risk: Vertex paid about $10 billion for a franchise whose peak-sales case above $5 billion still depends on Palsonify's uptake and on atumelnant succeeding in Phase 3.

What is the Vertex Pharmaceuticals Incorpor (VRTX) forecast?

28 analysts publish price targets on VRTX, averaging $592.36 as of November 2026, or +10.1% against the $537.79 share price on November 16, 2026. The published targets run from $350.00 to $725.00, a moderate spread, and the ratings split 26 buy, 5 hold, 1 sell. Over the last six months there have been 11 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full VRTX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is VRTX a buy or a sell?

We give no verdict on Vertex Pharmaceuticals Incorpor. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. A durable, high-margin cystic fibrosis near-monopoly. Vertex remains effectively the only company selling root-cause CF therapies, and demand for Trikafta/Kaftrio continues to grow through label expansions into younger age groups and additional geographies. The most optimistic published target, $725.00, assumes this works close to its best case.

The case against. The central risk is revenue concentration: cystic fibrosis still accounts for the overwhelming majority of Vertex's sales, so any disruption, whether a safety signal, a competing modulator, or pricing pressure, would hit the core disproportionately, and the newer products remain small by comparison. The most pessimistic target, $350.00, is roughly what VRTX is worth if this bites instead.

Read the full bull and bear case on VRTX, including what would have to change to break either one. Walnut is not an investment adviser.

Has Vertex Pharmaceuticals Incorpor (VRTX) split its stock?

No. Vertex Pharmaceuticals Incorpor (VRTX) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Vertex Pharmaceuticals Incorpor (VRTX) valued?

Market cap, P/E and dividend yield at today's price are in the VRTX key stats above. The business figures below come from Vertex Pharmaceuticals Incorpor's reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$12.6 billion
  • Revenue growth (Q2 2026): ~12.5% year over year
  • Margins (TTM): ~38% operating, ~35% net
  • Net income (TTM): ~$4.4 billion; EPS ~$17.17
  • Revenue guidance (FY 2026): ~$12.95 billion to $13.1 billion
  • Dividend: None

As of October 2026: As of October 16, 2026, Vertex trades near 29 times trailing and 25 times forward earnings, a premium to the large-cap pharma average that reflects its high margins and near-monopoly economics in cystic fibrosis plus expectations for pain, cell therapy and now endocrinology. The roughly $10 billion Crinetics purchase means part of the valuation debate has moved from unproven pipeline assets to whether an acquired franchise can earn back its price. Vertex does not pay a dividend, so returns depend on earnings growth and the multiple; Q3 results on November 2 are expected to carry deal-related costs.

Which ETFs hold Vertex Pharmaceuticals Incorpor (VRTX)?

If you want VRTX exposure as part of a larger bundle, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

ETFName% in VRTXExpense ratio
BBHVanEck Biotech ETF8.2%0.35%
IBBiShares Biotechnology ETF7.62%0.44%
FTCSFirst Trust Capital Strength ETF2.2%0.53%

What themes does Vertex Pharmaceuticals Incorpor (VRTX) fit?

These are the investment theses VRTX naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Biotech

Vertex is a large, profitable biotech leader built on cystic fibrosis drugs and now a sickle cell gene therapy.

Pharmaceutical stocks

Held as part of the Pharmaceutical stocks theme.

Gene editing stocks

Held as part of the Gene editing stocks theme.

Who competes with Vertex Pharmaceuticals Incorpor (VRTX)?

Cystic fibrosis (limited direct competition)

In root-cause CF therapy Vertex has essentially no direct competitor, which is the source of its pricing power, but several companies including AbbVie and various private and academic groups have pursued next-generation CFTR modulators or alternative approaches such as gene and mRNA therapies. None has reached the market at scale, so the practical risk is a future entrant eroding a franchise Vertex has had largely to itself rather than present-day head-to-head competition.

Gene and cell therapy peers

In sickle cell disease, Casgevy competes with bluebird bio's gene therapy Lyfgenia and with standard-of-care treatments, while CRISPR Therapeutics is both Vertex's Casgevy partner and a broader gene-editing peer. In type 1 diabetes cell therapy and other advanced modalities, Vertex competes with a range of biotech companies developing islet, stem-cell, and gene-based approaches, an area where manufacturing complexity and durability of response are the main battlegrounds.

Pain and broad-portfolio pharma

Journavx competes in acute and chronic pain against opioids, generic non-opioid analgesics, and other companies developing novel pain mechanisms, where payer coverage and pricing versus cheap generics are decisive. More broadly, large diversified pharmaceutical firms such as Pfizer, Johnson and Johnson, and others compete with Vertex for pipeline assets, licensing deals, and acquisition targets as it pushes beyond cystic fibrosis.

Endocrinology (via Crinetics)

Palsonify enters an acromegaly market served mainly by injectable somatostatin analogs such as Novartis's Sandostatin and Ipsen's Somatuline, plus Chiasma's oral octreotide (Mycapssa, now owned by Amryt/Chiesi). Atumelnant would face Neurocrine Biosciences' Crenessity in congenital adrenal hyperplasia if approved.

What stocks are similar to Vertex Pharmaceuticals Incorpor (VRTX)?

Other names that sit close to VRTX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Vertex Pharmaceuticals Incorpor (VRTX)

There are three common ways to get VRTX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (BBH, IBB, FTCS), which spreads the position across many companies. Or build it into a focused thematic portfolio, so VRTX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where VRTX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Vertex Pharmaceuticals Incorpor (VRTX)

Vertex is a highly profitable cystic-fibrosis near-monopoly attempting to diversify into pain, cell therapy, diabetes, and kidney disease, so the investing debate centers on whether the newer launches and pipeline can meaningfully add to a franchise that already funds itself.

More on Vertex Pharmaceuticals Incorpor (VRTX)

Whether VRTX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is VRTX a buy or a sell?, and where the stock could go from here in the VRTX stock forecast.

For income investors, whether VRTX pays a dividend and how the payout looks is covered in does VRTX pay a dividend? And to weigh VRTX against a peer, read the full side-by-side comparisons: VRTX vs GILD and VRTX vs AMGN.

Wondering how VRTX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Vertex Pharmaceuticals Incorpor

Ask Walnut's AI anything about VRTX and see how it fits what you own.

FAQ

What does Vertex Pharmaceuticals do?

+

Vertex is a biotechnology company that makes medicines targeting the root cause of serious diseases. It is the dominant maker of cystic fibrosis therapies, led by Trikafta/Kaftrio and its successor Alyftrek, and has expanded into a non-opioid pain drug (Journavx), a CRISPR gene therapy for sickle cell disease and beta thalassemia (Casgevy), and pipeline programs in type 1 diabetes and kidney disease. It reported roughly $12.0 billion in 2025 revenue, about $12.6 billion over the trailing twelve months to June 2026, and in September 2026 it added an endocrinology franchise by acquiring Crinetics Pharmaceuticals.

Is VRTX a good stock to buy right now?

+

Whether VRTX suits a portfolio depends on an investor's goals, time horizon, and existing holdings, and Walnut is not an investment adviser. Supporters cite a highly profitable cystic-fibrosis near-monopoly, a cash-rich balance sheet, and a diversifying pipeline. Skeptics point to heavy CF concentration, clinical and regulatory risk in the pipeline, and a premium valuation. No single answer fits every investor.

Does Vertex pay a dividend?

+

No. Vertex does not pay a dividend and instead reinvests its substantial operating cash flow into research, development, and acquisitions to diversify beyond cystic fibrosis. As a result, investor returns depend entirely on earnings growth and the valuation multiple rather than on dividend income, which makes pipeline and launch execution the central drivers of the stock.

What is Vertex's main product?

+

Vertex's largest product is its cystic fibrosis franchise, historically Trikafta (sold as Kaftrio in Europe), a triple-combination therapy that treats the underlying CFTR protein defect in the majority of CF patients. In late 2024 Vertex began launching Alyftrek, a once-daily next-generation successor designed to extend the franchise and its patent protection. Cystic fibrosis still drives most of Vertex's revenue.

What is Casgevy?

+

Casgevy is a CRISPR/Cas9 gene-editing therapy developed by Vertex with CRISPR Therapeutics to treat sickle cell disease and transfusion-dependent beta thalassemia. It was among the first approved CRISPR medicines and can reduce or eliminate the painful vaso-occlusive crises of sickle cell disease. Because it requires specialized treatment centers and lengthy patient preparation, its revenue is ramping gradually rather than immediately.

How is Vertex diversifying beyond cystic fibrosis?

+

Vertex is diversifying through Journavx (suzetrigine), a non-opioid acute-pain drug now also in Phase 3 for diabetic peripheral neuropathic pain; Casgevy, its CRISPR gene therapy for blood disorders; zimislecel, a stem-cell islet therapy for type 1 diabetes with regulatory submissions expected in 2026; inaxaplin for APOL1-mediated kidney disease; and, since September 2026, the Crinetics portfolio of Palsonify for acromegaly and atumelnant for congenital adrenal hyperplasia and Cushing's syndrome. Non-cystic-fibrosis products supplied more than a quarter of revenue growth in early 2026.

What are the biggest risks for Vertex investors?

+

The main risks are revenue concentration in cystic fibrosis, clinical and regulatory risk across pipeline programs in diabetes, pain, and kidney disease that could fail or be delayed, a slow ramp for the gene therapy Casgevy, drug-pricing pressure, and a premium valuation that can derate sharply on disappointment. Eventual patent expirations on the CF franchise are a longer-term overhang partly addressed by the newer Alyftrek.

What is Vertex's outlook for 2026?

+

Vertex guided full-year 2026 total revenue to roughly $12.95 billion to $13.1 billion, up from about $12.0 billion in 2025, with non-cystic-fibrosis products expected to contribute $500 million or more. Growth drivers include continued Trikafta/Kaftrio and Alyftrek demand plus launches of Journavx and Casgevy, and the company expects key pipeline readouts and regulatory submissions, including zimislecel in type 1 diabetes. The Crinetics acquisition adds Palsonify sales from the fourth quarter onward. Analysts tracked by Yahoo Finance expect ~$13.3 billion of 2026 revenue, slightly above the guidance range, and ~$14.6 billion in 2027.

Why did Vertex buy Crinetics Pharmaceuticals?

+

To build a second large franchise outside cystic fibrosis. The roughly $10 billion all-cash deal, which closed in September 2026, brought Palsonify, a once-daily oral acromegaly treatment already on the US market, and atumelnant, in Phase 3 for congenital adrenal hyperplasia and Phase 2 for Cushing's syndrome. Vertex estimates their combined peak revenue at more than $5 billion.

How did Vertex do in its latest quarter?

+

In Q2 2026 Vertex reported revenue of ~$3.33 billion, up ~12.5% from a year earlier, and EPS of $4.73 against a $4.75 consensus, roughly in line. Q3 2026 results are scheduled for November 2, 2026, with consensus revenue of ~$3.43 billion and consensus EPS of only ~$0.04, a figure that points to one-time costs from the Crinetics acquisition.

How has VRTX stock performed in 2026?

+

As of October 16, 2026, VRTX closed near $504.24, up ~12% year to date and ~23% over one year, within a 52-week range of roughly $403 to $560. The 28 analysts tracked by Yahoo Finance have a mean target near $571. Walnut is not an investment adviser, so these figures describe the stock rather than forecast it.

Guides that feature VRTX

VRTX is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Vertex Pharmaceuticals Incorpor's investor relations page or your broker before making investment decisions.